Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Milby

Orthopaedic Surgery of the Spine Smyrna, GA Medical Doctor

NPI 1396063640 CMS profile 154327

3903 S Cobb Dr Se, Smyrna, GA 30080

Open in the dashboard

General payments

$164,047

161 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Milby of Smyrna, GA is reported in the CMS Open Payments database as having received $164,047 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $54,038 33
2024 General $46,347 38
2023 General $15,783 24
2022 General $29,933 32
2021 General $17,436 23
2020 General $331 7
2019 General $181 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Milby
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Andrew Milby were reported at $54,038. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Andrew Milby Orthopaedic Surgery of the Spine median Middle half National median
2019 $181 $2,106 $337–$18,608 $163
2020 $331 $1,213 $156–$15,082 $114
2021 $17,436 $1,834 $271–$15,617 $132
2022 $29,933 $2,015 $320–$17,036 $149
2023 $15,783 $1,925 $336–$14,599 $160
2024 $46,347 $2,110 $341–$12,483 $164
2025 $54,038 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $119,832 109 payments
  2. VB Spine LLC $41,187 15 payments
  3. Alphatec Spine, Inc $1,934 7 payments
  4. NuVasive, Inc. $579 19 payments
  5. Medtronic, Inc. $184 4 payments
  6. Medical Device Business Services, Inc. $143 1 payment
  7. Globus Medical, Inc. $131 3 payments
  8. Biocomposites Inc $24 1 payment
  9. Smith+Nephew, Inc. $17 1 payment
  10. Medtronic USA, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $142,375 19 payments
  2. Travel and Lodging $16,197 49 payments
  3. Food and Beverage $5,475 93 payments
Products named General payments · program years 2019–2025
  1. CASCADIA INTERBODY SYSTEM Spine $45,042 23 payments
  2. EVEREST SPINAL SYSTEM $37,744 34 payments
  3. CANYON RETRACTOR SYSTEMS $24,032 3 payments
  4. YUKON OCT SPINAL SYSTEM $18,355 5 payments
  5. CASCADIA INTERBODY SYSTEM Spine $15,265 2 payments
  6. XIA 3 $11,571 3 payments
  7. NIAGARA LATERAL ACCESS SYSTEM $11,000 4 payments
  8. MONTEREY AL $9,176 2 payments
  9. OASYS $9,000 1 payment
  10. XIA 3 SYSTEM - SERRATO $7,017 2 payments
  11. Other $13,923 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

566

Median for Orthopedic Surgery: 203

Drug cost

$5,632

Median for Orthopedic Surgery: $1,433

Branded share of claims

14.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 110 $1,115
Oxycodone Hcl Generic 97 $956
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 64 $857
Methocarbamol Generic 66 $491
Morphine Sulfate Er Morphine Sulfate Brand 16 $396
Tizanidine Hcl Generic 38 $394
Pregabalin Generic 25 $269
Tramadol Hcl Generic 34 $221
Hydromorphone Hcl Generic 30 $211
Celecoxib Generic 12 $188

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$110,481

Medicare's payments for the services billed

Medicare patients

168

Average age 71

Services billed

619

105 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Depression 30%
Osteoporosis 27%
Ischemic heart disease 26%
Diabetes 24%
Chronic kidney disease 19%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record